South African Tuberculosis Vaccine Initiative (SATVI)
The South African Tuberculosis Vaccine Initiative (SATVI), is a world leader in TB vaccine clinical research.
The mission of SATVI, based at the University of Cape Town (UCT), is development of new and effective vaccinat ion strategies against tuberculosis (TB). A new, effective vaccine has the potential to save hundreds of thousands of lives world-wide.
We are testing multiple new vaccine candidates in clinical trials. We are also completing projects to address critical clinical, epidemiological, immunological and human genetic questions in TB vaccine development. Our activities are within an academic context, and thus include the training of postgraduate students.
The SATVI field site is located in the Boland region, 110km outside Cape Town, where the rate of TB is amongst the highest recorded in the world. This rural area of about 12,000 square kilometers has a population of about 350,000, of whom more than 20,000 have participated in our studies to date.
SATVI's leadership is based in Cape Town at UCT's Health Sciences Faculty. They are supported by a 200 strong multi-skilled team and high-tech laboratory facilities in both Cape Town and Worcester.
Our success as a clinical TB vaccine research site in the world is evident from manuscripts published in high impact journals, funding support from multiple international funding agencies, invited presentations at international conferences and representation on international policy bodies.(Click here for more detail.)
Many of SATVI's activities are conducted within large consortia that involve investigators from other parts of Africa, Europe, the US and Asia. We are also leading the Vaccines for Africa (VACFA) initiative on the continent.